Shield Therapeutics (LSE:STX) has taken full control of the US commercialisation of its iron deficiency treatment ACCRUFeR, ending a four-year co-commercialisation arrangement with Viatris. The deal, announced on 27 August 2026 and expected to complete on 30 September, follows interim results showing the specialty pharmaceutical company reached a small operating profit in the first half of 2026 and remains on track for operating profitability for the full year.

What the Company Does

Shield Therapeutics is a commercial-stage pharmaceutical company focused on iron deficiency. Its sole marketed product, ferric maltol, is an oral iron therapy sold as ACCRUFeR in the United States and as Feraccru in Europe and other markets. The company sells directly in the US and relies on licensing partners elsewhere, including Norgine in Europe and the UK, ASK Pharm in China, KYE in Canada and partners in Japan and Korea. During 2026 the product's label was extended to younger patients: US approval for those aged 10 and over came on 1 April, followed by European and UK approvals for patients aged 12 and over in May and July.

Latest Developments

Under the Viatris agreement, Shield takes over all US commercial activity, including the sales force previously run jointly. Viatris receives no upfront payment, while Shield keeps the gross profit from US sales and pays Viatris a royalty on net sales for five years, starting in the high single digits and rising to the mid-teens. Previously Shield paid Viatris 45% of US net product revenue. Chief executive Anders Lundstrom called the deal an important strategic milestone that gives the company control of its most important market. Shield expects it to improve margins, cash generation and profitability, although it acknowledged a higher cost base.

In late July the company also announced publication of results from its Phase 3 paediatric trial of ACCRUFeR.

Financial Picture

Interim results published on 20 August 2026 showed revenue for the six months to 30 June rising 42% to $30.4m. US ACCRUFeR revenue grew 5% to $20.1m, while milestones and royalties from outside the US contributed $10.3m, including a $7.9m development milestone from ASK Pharm. Prescriptions rose 21% to about 102,000, but the average net selling price fell to $199 from $214, partly because of Medicaid changes in New York that sharply reduced approved prescriptions there from May.

The company recorded an operating profit of $0.2m, compared with a $5.8m loss a year earlier, and its loss for the period narrowed to $2.3m from $9.5m. Cash was $8.3m at 30 June, down from $11.6m at the end of 2025. Shield has a $24.9m loan from Runway Growth Capital maturing in September 2028, with no scheduled principal repayments until the third quarter of 2027. The directors said the group has sufficient cash for at least 12 months. No dividend is paid.

Sector and Index Context

Shield is one of a small number of commercial-stage drug companies on the FTSE AIM All Share Index. Smaller pharmaceutical groups selling into the US face intense competition, complex reimbursement and pricing pressure from payers, making market access as important as clinical data.

Key Risks

Taking on the US sales force increases fixed costs, so the deal's benefits depend on continued prescription growth. Pricing pressure and changes in insurer or Medicaid coverage, as seen in New York, can hit revenue quickly. The company's cash balance is modest relative to its debt, and part of its first-half revenue came from one-off milestones that may not recur.

What to Watch Next

Investors will watch for a third-quarter trading update showing how the business has performed since taking full US control, confirmation of operating profitability for 2026, and progress with further partner milestones and paediatric uptake.